Peptide Payment Processing Compliance Guide
If you sell research peptides and accept credit cards, your payment processing is the single greatest operational risk to your business. Many peptide merchants lose or change processing because their processor inaccurately classified them, failed to disclose the actual business model to the acquiring bank, or did not maintain the documentation high-risk underwriting expects.
This guide covers what you need to know to keep your merchant account open and your revenue flowing.
Why peptide merchants are classified as high-risk
Payment processors and acquiring banks assess risk across several dimensions. Research peptides trigger concerns in multiple categories:
- Regulatory ambiguity — products exist in a gray area between supplements and pharmaceuticals, with evolving FDA, FTC, card-network, and acquiring-bank expectations
- Elevated chargebacks — customer disputes arise from misunderstanding research-only status, delayed results, and buyer's remorse
- Reputational risk — banks fear association with products that could become the subject of future regulatory action
- International complexity — cross-border sales introduce multi-jurisdiction compliance requirements
The number one reason accounts get shut down
Incorrect merchant coding is one of the biggest causes of account termination for peptide merchants. Payment facilitators sometimes misclassify businesses to bypass underwriting restrictions.
When an acquiring-bank audit or monitoring review catches the misclassification, the result can be termination and a reserve hold, often 90–180 days, to cover potential disputes and chargebacks.
The review process can move quickly from flag to funding hold, especially when the website, descriptor, chargeback history, or product claims do not match the underwriting file.
Essential compliance documentation
Legitimate peptide processing requires documentation that demonstrates you operate a compliant, research-focused business. Every merchant should maintain:
- Third-party lab testing certificates (Certificate of Analysis for each product)
- Prominent "Research Use Only" disclaimers across all customer touchpoints
- Robust age verification (21+ or 18+ depending on jurisdiction)
- Transparent refund and return policies, prominently displayed
- Terms of Service explicitly prohibiting human consumption
- Customer acknowledgment checkbox confirming research-only intent at checkout
Marketing compliance: what to avoid
Processors routinely scan merchant websites for compliance. These subtle missteps trigger account reviews:
- Implied health benefits or therapeutic claims ("promotes recovery," "supports cognitive function")
- Before/after photos suggesting human consumption
- Testimonials describing personal results
- Dosing instructions that imply human use
- Social content promoting off-label use
- Medical terminology suggesting treatment, cure, or disease prevention
Chargeback management: the make-or-break metric
Visa and Mastercard monitor chargeback ratios rigorously. Thresholds vary by card brand, region, count, and program, but common monitoring triggers include:
- Standard monitoring: can begin around 0.9–1.0% dispute ratios, depending on card brand and program
- Excessive monitoring: can begin at higher thresholds; Visa, Mastercard, and acquirer-specific rules differ
- Industry reality: peptide merchants can exceed monitoring levels without strong fulfillment, customer communication, and dispute prevention
Effective chargeback management requires:
- Proactive communication — shipping confirmations, tracking updates, delivery notifications
- Clear billing descriptors — customers must recognize your business on their statement
- Responsive customer service — resolve disputes before they escalate to chargebacks
- Compelling evidence packages — records of consent, delivery proof, communication logs
The true cost of non-compliance
A processor termination isn't just an inconvenience — it's financially devastating:
- Frozen funds — reserves held 90–180 days after termination
- MATCH / TMF exposure — certain terminations can lead to card-network database placement, making future underwriting much harder
- Lost revenue — days or weeks offline during processor transitions
- Customer trust erosion — payment failures damage your brand
- Legal exposure — compliance violations can trigger regulatory investigations
How ResearchPay approaches compliance differently
We spent 18 months building relationships with acquiring banks who understand the research peptide vertical. Every merchant is fully disclosed to the acquiring bank from day one. No intentional miscoding. No undisclosed aggregation layers. No hidden high-risk placement.
If you're processing peptides and want a stable, bank-backed merchant account, open an account or talk to our underwriting team.